Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Efficacy & Safety for LN144 with Pembrolizumab with High Risk Stage IIIb-dResectable Melanoma

First Posted Date
2024-01-05
Last Posted Date
2024-12-05
Lead Sponsor
James Isaacs, MD
Target Recruit Count
12
Registration Number
NCT06190249
Locations
🇺🇸

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

First Posted Date
2024-01-05
Last Posted Date
2024-07-16
Lead Sponsor
Mayo Clinic
Target Recruit Count
27
Registration Number
NCT06191887
Locations
🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

First Posted Date
2024-01-05
Last Posted Date
2024-12-03
Lead Sponsor
Genmab
Target Recruit Count
1080
Registration Number
NCT06191744
Locations
🇺🇸

Rocky Mountain Cancer Centers - Boulder /ID# 261203, Boulder, Colorado, United States

🇺🇸

Christiana Care Health Service /ID# 261207, Newark, Delaware, United States

🇺🇸

Oncology Hematology Care, Inc - Blue Ash /ID# 261204, Cincinnati, Ohio, United States

and more 192 locations

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

First Posted Date
2024-01-05
Last Posted Date
2024-12-20
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
30
Registration Number
NCT06193486
Locations
🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL

First Posted Date
2024-01-03
Last Posted Date
2024-01-03
Lead Sponsor
National Research Center for Hematology, Russia
Target Recruit Count
100
Registration Number
NCT06188676
Locations
🇷🇺

National Research Center for Hematology, Moscow, Russian Federation

Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL

First Posted Date
2023-12-19
Last Posted Date
2023-12-19
Lead Sponsor
PETHEMA Foundation
Target Recruit Count
150
Registration Number
NCT06175702

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

First Posted Date
2023-12-15
Last Posted Date
2024-12-18
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
478
Registration Number
NCT06172296
Locations
🇺🇸

Blank Children's Hospital, Des Moines, Iowa, United States

🇺🇸

Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

🇺🇸

Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 115 locations

The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)

First Posted Date
2023-12-07
Last Posted Date
2023-12-07
Lead Sponsor
Henan Cancer Hospital
Target Recruit Count
20
Registration Number
NCT06160362
Locations
🇨🇳

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China

Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients

First Posted Date
2023-12-04
Last Posted Date
2023-12-18
Lead Sponsor
Tanta University
Target Recruit Count
44
Registration Number
NCT06155331
Locations
🇪🇬

Hagar Dewidar, Tanta, Elgharbya, Egypt

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

First Posted Date
2023-12-01
Last Posted Date
2024-12-20
Lead Sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Target Recruit Count
130
Registration Number
NCT06153251
Locations
🇪🇸

Clinica Universidad de Navarra, Pamplona, Navarra, Spain

🇫🇷

Hôpital Saint-Louis, Paris, France

🇩🇪

Universitaetsklinikum Heidelberg, Heidelberg, Germany

and more 16 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy